✦ LIBER ✦

GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial

✍ Scribed by Mohamad A. Hussein; Kate Sandstrom; Paul Elson; James Finke; Denise McLain; Patricia Rayman; Lisa A. Rybicki; Ronald A. Bukowski

Publisher: Springer-Verlag
Year: 2001
Tongue: English
Weight: 101 KB
Volume: 127
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s004320100250

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of mitoxantrone and granul

Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies

✍ Joan H. Schiller; Barry Storer; Rhoda Arzoomanian; Kendra Tutsch; Dona Alberti; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 806 KB

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

A phase II study of oxaliplatin, docetax

A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma

✍ Frederick Locke; Joseph I. Clark; Thomas F. Gajewski 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 268 KB

A Phase I–II trial of polyethylene glyco

A Phase I–II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma

✍ Neeraj R. Agrawal; Ronald M. Bukowski; Lisa A. Rybicki; Joanne Kurtzberg; Lewis 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND Multiple myeloma remains an incurable disease. New agents are needed to improve therapy for patients with this disease. Previous investigators evaluated in vitro sensitivity of myeloma cells to polyethylene glycol‐conjugated L‐asparaginase (PEG‐L‐asparaginase) using the h

Extended follow-up of a phase II trial i

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: : Final time-to-event results from the SUMMIT trial

✍ Paul G. Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jaganna 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views